logo
Cybersecurity Jobs That Will Dominate 2026: INE Security Prepares Professionals for the Most Critical Roles

Cybersecurity Jobs That Will Dominate 2026: INE Security Prepares Professionals for the Most Critical Roles

Yahoo17-06-2025

Cary, NC, June 17, 2025 (GLOBE NEWSWIRE) -- INE Security, a leading global cybersecurity training and IT security training provider, is releasing new analysis of cybersecurity roles that will dominate the 2026 job market. Based on a comprehensive analysis of industry data and research released at major cybersecurity conferences, including RSA Conference 2025, GISEC Global 2025, and worldwide Black Hat events, INE Security has identified cybersecurity job roles where the highest market demand intersects with hands-on technical expertise.
"Skill shortages are a major concern throughout the cybersecurity industry, particularly in mission-critical roles,' said Tracy Wallace, INE Security's Director of Content Development. 'INE Security's hands-on cybersecurity training methodology creates job-ready professionals in the areas where technical expertise can make the greatest immediate impact. Our 3,100+ browser-based labs don't just teach concepts—they build the practical IT security training skills that organizations need right now."
Critical Cybersecurity Roles Shaping 2026:
Identity Security Posture Management (ISPM) Specialists: With identity-related breaches continuing to plague organizations, ISPM specialists will be essential for enterprises seeking to uncover and address identity risks across hybrid cloud and on-premises systems. RSAC 2025 emphasized new ISPM capabilities and innovations to protect passwordless environments, while major vendors announced ISPM solutions as core offerings.
: Comprehensive Active Directory security training, Identity and Access Management courses, and privilege escalation techniques integrated across the eJPT and eCPPT learning paths provide unparalleled preparation for ISPM roles
: More than 500 hands-on labs focused on identity security give professionals the practical expertise enterprises desperately need to secure hybrid environments
Career Pathway: Clear progression from fundamental identity concepts to advanced enterprise identity architecture management
Crowdsourced Red Team Specialists: The cybersecurity industry is exploring offensive security through distributed approaches. At RSAC 2025, Bugcrowd launched the industry's first Crowdsourced Red Team as a Service platform, connecting organizations to global networks of vetted ethical hackers for real-time, intelligence-led testing. This model brings the potential for massive scale and flexibility to traditionally resource-heavy security assessments.
INE Security Training Advantage: Proven pentester training progression from eJPT (Junior Penetration Tester) through eCPPT (Certified Professional Penetration Tester) to eWPTX (Web Application Penetration Tester eXtreme) creates the exact ethical hacking expertise needed for distributed red team operations
: Students practice authentic attack scenarios through browser-based labs that simulate crowdsourced testing environments
: INE Security's pentester certifications are trusted by Fortune 500 companies globally, specifically for roles requiring hands-on offensive security expertise
Mobile Threat Analysts: Cyber attackers are increasingly prioritizing mobile over desktop environments. Zimperium's 2025 Global Mobile Threat Report showed that smishing now comprises over two-thirds of mobile phishing attacks. Organizations need specialists focused exclusively on mobile security infrastructure.
INE Security Training Advantage: The eMAPT (Mobile Penetration Testing) certification provides foundational mobile security expertise, positioning graduates for the expanding mobile defense field
Expanding Curriculum: INE Security is developing advanced mobile defense training to address enterprise mobile threat intelligence and incident response
Market Opportunity: As one of the few providers offering hands-on mobile security labs, INE Security graduates enter this high-demand field with immediate practical capabilities
AI Security Specialists/Engineers: The demand for AI security expertise has reached unprecedented levels. RSA Conference 2025 featured over 100 sessions dealing with artificial intelligence, with attendees noting the event had transformed into "RSAI" rather than RSAC. GISEC Global 2025 was held under the theme 'Securing an AI-Powered Future,' emphasizing AI governance and digital ethics as critical areas requiring immediate attention.
INE Security Training Advantage: INE Security's strong training materials in threat detection and analysis, combined with foundational AI skills, provide professionals with transferable skills applicable to AI security roles
Market Opportunity: Represents the highest-growth career opportunity in cybersecurity as organizations deploy AI-powered security tools while defending against AI-enhanced attacks
Industry Development: The cybersecurity training industry is scrambling to develop AI security courses to meet skyrocketing demand
Cloud Security Engineers: Cloud Security Engineers are integral to organizational resilience as businesses accelerate cloud adoption. With 45% of organizations reporting unfilled cloud security roles and experienced professionals commanding salaries above $155,000 annually, this represents one of the highest-demand technical specializations. AWS Certified Security - Specialty is now recognized as one of the highest-paying technical cloud positions in the world, with an average global salary of $158,594.
: Comprehensive cloud certification preparation across AWS, Azure, and Google Cloud platforms with dedicated learning paths for AWS Solutions Architect Associate, AWS SysOps Administrator Associate, Azure Security Engineer Associate (AZ-500), and Azure Administrator Associate (AZ-104)
Hands-On Cloud Labs: 130+ hands-on labs specifically designed for cloud security scenarios, plus additional cloud security collections in Skill Dive for real-world practice
Security-First Approach: INE Security's "learn by doing" cybersecurity education methodology ensures graduates develop practical cloud security skills that directly address enterprise needs for securing AWS, Azure, and GCP environments
Training That Delivers Career Resilience
INE Security's approach addresses the intersection of market demand and practical skills development:
Immediate Market Entry: Identity security, red team operations, and mobile defense roles offer immediate career opportunities for technically skilled professionals
Skills Premium: Organizations investing in cybersecurity education programs are overwhelmingly more likely to retain cybersecurity professionals, according to a 2024 LinkedIn workforce study, directly addressing skills shortages in high-demand technical roles
Future-Proofing: As digital transformation accelerates, technical security roles address fundamental infrastructure needs that will intensify through 2026 and beyond
Clear ROI: Professionals can immediately contribute to identity security, red team operations, and mobile defense initiatives with hands-on expertise
"The convergence of identity threats, sophisticated attacks, and mobile vulnerabilities creates new opportunities for cybersecurity professionals who combine technical depth with practical experience," continued Wallace. "INE Security's strength lies in preparing professionals for roles where hands-on technical skills directly address critical business security needs."
About INE Security
INE Security is the premier provider of online networking and cybersecurity training and cybersecurity certifications. Harnessing a powerful hands-on lab platform, cutting-edge technology, a global video distribution network, and world-class instructors, INE Security is the top training choice for Fortune 500 companies worldwide for cybersecurity training in business and for IT professionals looking to advance their careers. INE Security's suite of learning paths and preparation for professional certifications offers an incomparable depth of expertise across cybersecurity and is committed to delivering advanced technical training for cybersecurity jobs while also lowering the barriers worldwide for those looking to enter and excel in an IT career.
CONTACT: Kathryn Brown INE kbrown@ine.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

First Online Dispensary That Ships to All States Debuts
First Online Dispensary That Ships to All States Debuts

Hamilton Spectator

time9 minutes ago

  • Hamilton Spectator

First Online Dispensary That Ships to All States Debuts

Austin, TX, June 30, 2025 (GLOBE NEWSWIRE) -- Area 52 today launches its nationwide fulfillment service, solidifying its position as the first online dispensary that ships to all states. This is a groundbreaking development for cannabis consumers, particularly in states with limited recreational access, providing a safe, federally legal, and reliable way to buy weed online and secure direct-to-home weed delivery. (click photo to check customer reviews) A Legal Cannabis Solution for Texas, Florida, and North Carolina Residents in states like Texas, Florida, and North Carolina have historically faced a significant challenge: a strong demand for cannabis with no state-level legal framework for recreational sales. Area 52 directly solves this problem. As the leading online dispensary that ships to all states, we provide a crucial access point for quality THC products. Our platform now serves as the go-to online dispensary for customers in Florida seeking compliant cannabis. For residents throughout Texas, from Dallas to Houston, our weed delivery service offers a discreet and legal alternative. Likewise, any adult in North Carolina looking to legally buy weed online can now do so with confidence through our verified system. How Nationwide Weed Delivery is Possible: Farm Bill Compliance The ability for Area 52 to function as an online dispensary that ships to all states is based on strict adherence to the 2018 Farm Bill. This federal law legalized hemp and its derivatives, provided the final product contains less than 0.3% Delta-9 THC by dry weight. Every product we offer meets this standard, making it federally legal to ship across state lines. This allows us to offer legal weed delivery of potent and effective products like Delta-8 THC, HHC, and other hemp-derived cannabinoids. Key Features of the Area 52 Online Dispensary: Area 52 is now the definitive answer for millions of Americans asking where they can buy weed online safely and legally. Our commitment to compliance, transparency, and accessibility makes us the most trusted online dispensary for nationwide service. To browse the full product catalog and experience the convenience of the leading online dispensary that ships to all states, visit – or click here to read customer reviews .

First Online Dispensary That Ships to All States Debuts
First Online Dispensary That Ships to All States Debuts

Yahoo

time33 minutes ago

  • Yahoo

First Online Dispensary That Ships to All States Debuts

Austin, TX, June 30, 2025 (GLOBE NEWSWIRE) -- Area 52 today launches its nationwide fulfillment service, solidifying its position as the first online dispensary that ships to all states. This is a groundbreaking development for cannabis consumers, particularly in states with limited recreational access, providing a safe, federally legal, and reliable way to buy weed online and secure direct-to-home weed delivery. (click photo to check customer reviews)A Legal Cannabis Solution for Texas, Florida, and North Carolina Residents in states like Texas, Florida, and North Carolina have historically faced a significant challenge: a strong demand for cannabis with no state-level legal framework for recreational sales. Area 52 directly solves this problem. As the leading online dispensary that ships to all states, we provide a crucial access point for quality THC products. Our platform now serves as the go-to online dispensary for customers in Florida seeking compliant cannabis. For residents throughout Texas, from Dallas to Houston, our weed delivery service offers a discreet and legal alternative. Likewise, any adult in North Carolina looking to legally buy weed online can now do so with confidence through our verified system. How Nationwide Weed Delivery is Possible: Farm Bill Compliance The ability for Area 52 to function as an online dispensary that ships to all states is based on strict adherence to the 2018 Farm Bill. This federal law legalized hemp and its derivatives, provided the final product contains less than 0.3% Delta-9 THC by dry weight. Every product we offer meets this standard, making it federally legal to ship across state lines. This allows us to offer legal weed delivery of potent and effective products like Delta-8 THC, HHC, and other hemp-derived cannabinoids. Key Features of the Area 52 Online Dispensary: Nationwide Access: We are a true online dispensary that ships to all states, ending the search for consumers in markets like Georgia, Tennessee, South Carolina, Texas, and Florida. Verified Quality & Safety: Every customer who wants to buy weed online can view third-party Certificates of Analysis (COAs) for every product, ensuring purity and legal compliance. Discreet and Fast Shipping: We provide professional, private weed delivery to your doorstep. Your order is handled with the utmost discretion from checkout to arrival. Area 52 is now the definitive answer for millions of Americans asking where they can buy weed online safely and legally. Our commitment to compliance, transparency, and accessibility makes us the most trusted online dispensary for nationwide service. To browse the full product catalog and experience the convenience of the leading online dispensary that ships to all states, visit – or .CONTACT: Area 52 3172 N Rainbow Blvd #22136 Las Vegas, NV 89108Sign in to access your portfolio

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Business Upturn

time5 hours ago

  • Business Upturn

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated Atumelnant Phase 2 trial results in congenital adrenal hyperplasia (CAH) to be featured in oral presentation Data from early-stage development program in Graves' hyperthyroidism and orbitopathy also to be featured SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug candidate, PALSONIFY™ (paltusotine)* and investigational candidate atumelnant, will be presented at the Endocrine Society's Annual Meeting, ENDO 2025, July 12-15, 2025, in San Francisco, California. 'ENDO 2025 will be an incredibly meaningful moment for Crinetics in our mission to be the premier endocrine-focused global pharmaceutical company,' said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. 'For our lead investigational candidate PALSONIFY for acromegaly, we are excited to present long-term data that continue to support the durable, consistent response profile it has shown in earlier pivotal trials. Additionally, compelling Phase 2 trial results from atumelnant in CAH and new data from one of our early-stage development programs demonstrate that the Crinetics pipeline can address significant unmet needs.' Four abstracts will report results from the PALSONIFY development program, including an oral presentation featuring open-label extension data from the registrational Phase 3 PATHFNDR trials. This presentation will highlight long-term efficacy, safety, and symptom control in people with acromegaly who switched from injectable somatostatin receptor ligands (SRLs) to once-daily oral PALSONIFY. In addition, Crinetics will present three poster presentations: one evaluating symptom stability in acromegaly, one analyzing patient-reported outcomes from both PATHFNDR-1 and PATHFNDR-2 and another on PATHFNDR-2 open-label extension data. Together, these abstracts show PALSONIFY continues to be well tolerated, while providing consistent biochemical and symptomatic disease control. Crinetics will also present three abstracts from its atumelnant clinical development program, including an oral presentation of Phase 2 trial results in congenital adrenal hyperplasia (CAH). Additional presentations focus on reduction of adrenal volume and rapid and sustained reductions in potent 11-oxygenated androgens, a novel biomarker, in Phase 2 trial participants. Beyond its two lead programs, Crinetics will present new data from its early-stage pipeline, including data from CRN12755 for Graves' hyperthyroidism and orbitopathy. Additional presentation details are shown below. All times are PT: *The U.S. Food and Drug Administration recently conditionally approved PALSONIFY as the trade name for paltusotine, our once-daily, oral investigational candidate for acromegaly. PALSONIFY™ (paltusotine) Presentations Title: Paltusotine Results in Improved Symptom Stability in Biochemically Controlled Acromegaly Authors: David Clemmons, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-043 Title: Effects of Paltusotine Treatment on Patient-Reported Symptoms of Acromegaly in Phase 3 Randomized Placebo-Controlled Studies (PATHFNDR-2 and PATHFNDR-1) Authors: Avery A. Rizio, PhD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-052 Title: Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension Authors: Beverly M. K. Biller, MD et. al. Date/Time: July 13, 2:45-3:00 PM Location: Session OR12-07 – Neuroendocrinology and Pituitary: Management of Pituitary Disorders – Room 201 Title: Once-Daily Oral Paltusotine in the Treatment of Patients With Biochemically Uncontrolled Acromegaly: Interim Results of the PATHFNDR-2 Open-Label Extension Authors: Monica R. Gadelha, MD, PhD et. al. Date/Time: July 14, 12:00–1:30 PM Location: Session P77 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (except Cushing) III – ENDOExpo: Poster Area; MON-069 Atumelnant Presentations Title: Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Tania A.S.S. Bachega, MD, PhD et. al. Date/Time: July 12, 12:15-1:45 PM Location: Session P18 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH I – ENDOExpo Poster Area: SAT-452 Title: Once-Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17‑Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Umasuthan Srirangalingam, MD, PhD et. al. Date/Time: July 12, 2:30-2:45 PM Location: Session OR07-06 – Adrenal (Excluding Mineralocorticoids): All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency – Room 204 Title: -Rapid and Sustained Reduction of 11-Oxygenated Androgens in Adults With Classic Congenital Adrenal Hyperplasia Following Once-Daily Oral Atumelnant (CRN04894): Results From a 12-Week, Phase 2, Open-Label Study Authors: Nicole Reisch, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P55 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH II – ENDOExpo Poster Area: SUN-438 Early-Stage Pipeline Presentations Title: Discovery and Characterization of an Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonist for the Treatment of Graves' Disease and Thyroid Eye Disease Authors: Eulalia A. Coutinho, PhD et. al. Date/Time: July 14, 12:00-1:30 PM Location: Session P92 – Thyroid Biology and Disease: Benign Thyroid Disorders (Auto-Immune) II – ENDOExpo Poster Area: MON-365 Crinetics Sponsored Science & Innovation Theaters Title: Optimizing Long-Term Control in Acromegaly: Key to Improved Patient Outcomes Presenters: Shlomo Melmed, MB ChB; Christian J. Strasburger, MD Date/Time: July 14, 9:30 AM-10:30 AM Location: Theater 1 Title: Navigating the Complexities & Challenges of Acromegaly Management Presenters: Lisa B. Nachtigall, MD; Laurence Katznelson, MD; Scott Struthers, PhD Date/Time: July 14, 12:30 PM -1:30 PM Location: Theater 1 About PALSONIFY™ (Paltusotine) Crinetics' lead development candidate, PALSONIFY, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It was designed to be a once-daily oral option for the control of acromegaly and carcinoid syndrome. In Phase 3 studies, once-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome, leading to the initiation of a Phase 3 trial for control of carcinoid syndrome in patients with neuroendocrine tumors. About Atumelnant Atumelnant, Crinetics' second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with the Phase 3 CALM-CAH trial and a Phase 1/2b trial in ADCS currently enrolling patients. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the plans and timelines for the commercial launch PALSONIFY if approved; the potential clinical benefits of our TSHR antagonist, CRN12755, in patients across multiple indications, and the anticipated timing of clinical trials, registration applications or the therapeutic potential for our development candidates. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'upcoming' or 'continue' or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, initial or topline data that we report may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; geopolitical events may disrupt Crinetics' business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the success of Crinetics' clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics' drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading 'Risk Factors' in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Media: Natalie Badillo Head of Corporate Communications [email protected] (858) 345-6075

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store